Advanced Solid Tumor Cancer Clinical Trial
| NCT number | NCT06188975 |
| Other study ID # | C24-918 |
| Secondary ID | |
| Status | Available |
| Phase | |
| First received | |
| Last updated |
This is an expanded access program (EAP) for eligible participants. This program is designed to provide access to ABBV-CLS-484 prior to approval by the local regulatory agency. Availability will depend on territory eligibility. A medical doctor must decide whether the potential benefit outweighs the risk of receiving an investigational therapy based on the individual patient's medical history and program eligibility criteria.
| Status | Available |
| Enrollment | 0 |
| Est. completion date | |
| Est. primary completion date | |
| Accepts healthy volunteers | |
| Gender | All |
| Age group | N/A and older |
| Eligibility | Inclusion Criteria: - Exclusion Criteria: - |
| Country | Name | City | State |
|---|---|---|---|
| n/a | |||
| Lead Sponsor | Collaborator |
|---|---|
| Calico Life Sciences LLC |
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Recruiting |
NCT04777994 -
A Phase 1 Study With ABBV-CLS-484 in Subjects With Locally Advanced or Metastatic Tumors
|
Phase 1 | |
| Recruiting |
NCT04389281 -
X-ray Psoralen Activated Cancer Therapy in Head and Neck, Breast, Sarcoma and Melanoma
|
Phase 1 |